Clinical trial
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02086604 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 18, 2014
- Completion date
- January 12, 2022
- Enrollment
- 37 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.